Cargando…
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
OBJECTIVE: We investigated the mechanistic and pharmacological properties of anifrolumab, a fully human, effector-null, anti-type I interferon (IFN) alpha receptor 1 (IFNAR1) monoclonal antibody in development for SLE. METHODS: IFNAR1 surface expression and internalisation on human monocytes before...
Autores principales: | Riggs, Jeffrey M, Hanna, Richard N, Rajan, Bhargavi, Zerrouki, Kamelia, Karnell, Jodi L, Sagar, Divya, Vainshtein, Inna, Farmer, Erika, Rosenthal, Kimberly, Morehouse, Chris, de los Reyes, Melissa, Schifferli, Kevin, Liang, Meina, Sanjuan, Miguel A, Sims, Gary P, Kolbeck, Roland |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890856/ https://www.ncbi.nlm.nih.gov/pubmed/29644082 http://dx.doi.org/10.1136/lupus-2018-000261 |
Ejemplares similares
-
Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
por: Tummala, Raj, et al.
Publicado: (2018) -
Anifrolumab for systemic lupus erythematosus
Publicado: (2022) -
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
por: Tummala, Raj, et al.
Publicado: (2021) -
Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
por: Merrill, Joan T, et al.
Publicado: (2018) -
IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c(hi)T-bet(+) B cells in SLE
por: Wang, Shu, et al.
Publicado: (2018)